Company intelligence / Profile preview

Sen-Jam Pharmaceutical

Huntington, New York, United Statessen-jam.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Sen-Jam has two Phase 2 clinical trial assets (SJP-001 and SJP-002C). SJP-002C has shown promising results in a recently completed Phase 2 clinical trial for upper respiratory infections including COVID-19. The Phase 2 Clinical Trial for SJP-002C was scheduled to be completed in summer 2024[8].

Therapeutic areas: PsychiatryMetabolic DisordersRheumatologyEndocrinologyImmunologyOtherInfectious Diseases
Modalities: Small moleculescombination therapies
Industry: Biotech

Drug pipeline

14 assets

SJP002

13 more assets in the full pipeline.

Request access →

Partnerships

KVK-Tech (specialty pharmaceutical manufacturer)[8]

Beyond the preview

Go deeper on Sen-Jam Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sen-Jam Pharmaceutical.

Explore the full profile